These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34538077)

  • 1. Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression.
    Sushentsev N; Caglic I; Rundo L; Kozlov V; Sala E; Gnanapragasam VJ; Barrett T
    Br J Radiol; 2022 Mar; 95(1131):20210842. PubMed ID: 34538077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
    Morgan VA; Riches SF; Thomas K; Vanas N; Parker C; Giles S; Desouza NM
    Br J Radiol; 2011 Jan; 84(997):31-7. PubMed ID: 21172965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
    Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
    Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software.
    Le Nobin J; Orczyk C; Deng FM; Melamed J; Rusinek H; Taneja SS; Rosenkrantz AB
    BJU Int; 2014 Dec; 114(6b):E105-E112. PubMed ID: 24673731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance.
    Sushentsev N; Rundo L; Blyuss O; Nazarenko T; Suvorov A; Gnanapragasam VJ; Sala E; Barrett T
    Eur Radiol; 2022 Jan; 32(1):680-689. PubMed ID: 34255161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring Tumor Volume in Patients With Prostate Cancer Undergoing Active Surveillance: Is MRI Apparent Diffusion Coefficient Indicative of Tumor Growth?
    Morgan VA; Parker C; MacDonald A; Thomas K; deSouza NM
    AJR Am J Roentgenol; 2017 Sep; 209(3):620-628. PubMed ID: 28609110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance.
    Tamada T; Dani H; Taneja SS; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Sep; 42(9):2340-2345. PubMed ID: 28396920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer.
    Wang X; Tu N; Qin T; Xing F; Wang P; Wu G
    AJR Am J Roentgenol; 2018 Oct; 211(4):797-804. PubMed ID: 30085835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume.
    Simpkin CJ; Morgan VA; Giles SL; Riches SF; Parker C; deSouza NM
    Br J Radiol; 2013 Apr; 86(1024):20120469. PubMed ID: 23426849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI.
    Doo KW; Sung DJ; Park BJ; Kim MJ; Cho SB; Oh YW; Ko YH; Yang KS
    Eur Radiol; 2012 Aug; 22(8):1812-9. PubMed ID: 22466514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness.
    Vargas HA; Akin O; Franiel T; Mazaheri Y; Zheng J; Moskowitz C; Udo K; Eastham J; Hricak H
    Radiology; 2011 Jun; 259(3):775-84. PubMed ID: 21436085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging.
    Rosenkrantz AB; Kopec M; Kong X; Melamed J; Dakwar G; Babb JS; Taouli B
    J Magn Reson Imaging; 2010 Jun; 31(6):1387-94. PubMed ID: 20512891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of MRI texture analysis for predicting new Gleason grade group.
    He X; Xiong H; Zhang H; Liu X; Zhou J; Guo D
    Br J Radiol; 2021 May; 94(1121):20210005. PubMed ID: 33684304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification of prostate cancer utilizing apparent diffusion coefficient value and lesion volume on multiparametric MRI.
    Salami SS; Ben-Levi E; Yaskiv O; Turkbey B; Villani R; Rastinehad AR
    J Magn Reson Imaging; 2017 Feb; 45(2):610-616. PubMed ID: 27405584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient as a predictive biomarker of prostate cancer progression: value of fast and slow diffusion components.
    Giles SL; Morgan VA; Riches SF; Thomas K; Parker C; deSouza NM
    AJR Am J Roentgenol; 2011 Mar; 196(3):586-91. PubMed ID: 21343500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.
    van As NJ; de Souza NM; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC
    Eur Urol; 2009 Dec; 56(6):981-7. PubMed ID: 19095345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
    Lim C; Flood TA; Hakim SW; Shabana WM; Quon JS; El-Khodary M; Thornhill RE; El Hallani S; Schieda N
    J Magn Reson Imaging; 2016 Mar; 43(3):726-36. PubMed ID: 26303719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
    Mazaheri Y; Shukla-Dave A; Hricak H; Fine SW; Zhang J; Inurrigarro G; Moskowitz CS; Ishill NM; Reuter VE; Touijer K; Zakian KL; Koutcher JA
    Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.